Breathe Well Live Well
|
Skyepharma launches Flutiform in France for asthma
The Pharma Letter UK drug delivery specialist Skyepharma (LSE: SKP) has received regulatory approval and agreement on pricing reimbursement for asthma treatment Flutiform in France. Skyepharma's licensee Mundipharma, responsible for the development and … Skyepharma Jumps As It Launches Flutiform in France |
View full post on asthma – Google News
|
SkyePharma launches asthma treatment in Germany
Stock Market Wire flutiform® was approved for the treatment of asthma maintenance therapy in Germany by its regulatory authority, Bundesinstitut für Arzneimittel und Medizinprodukte (BfARM), in July. Following the launch offlutiform® in Germany, a milestone of €4.0m is … SkyePharma Launches Flutiform In Germany – Quick Facts |
View full post on asthma – Google News
|
SkyePharma soars on asthma drug approval
Telegraph.co.uk By Rachel Cooper, City Reporter SkyePharma has been hurt by concerns over its asthma therapy, Flutiform, with the share price taking a tumble just before Christmas as traders learnt of another delay to its European approval. SkyePharma asthma drug wins European backing SkyePharma's asthma drug wins European backing |
View full post on asthma – Google News
|
SkyePharma asthma drug wins European backing
Reuters UK By Paul Sandle | LONDON (Reuters) – SkyePharma said on Friday its lead product, asthma therapy Flutiform, had been recommended for approval by European regulators, doubling the value of the group's shares. Flutiform was referred to the European … SkyePharma's asthma drug wins European backing |
View full post on asthma – Google News
 This is Money |
MARKET REPORT: Skyepharma in a jam over asthma drug
This is Money … was run by its controversial founder Ian Gowrie Smith, who then had a history of over-promising and under-delivering, the City was up in arms after he announced a shock deeply-discounted £35m rights issue to develop Flutiform, its asthma treatment. … SkyePharma's Asthma Treatment Faces European Approval Delay; Shares Fall SkyePharma hit with European delay on Flutiform app SkyePharma lung drug faces European approval delay |
View full post on asthma – Google News
|
Skyepharma banking on European approval for Flutiform
Stock Market Wire The group said it was counting on European approval of asthma treatment Flutiform and launch in the second half of 2011. Revenue was up 4% to £58.1m from £55.9m, in line with management expectations. The rise was primarily due to a substantial increase … SkyePharma Moves To 2010 Pretax Profit, Sees Cash Outflows STOCKS NEWS UK-SkyePharma up on results Flutiform optimism Skyepharma turns in annual profit |
View full post on asthma – Google News
|
SkyePharma Moves To 2010 Pretax Profit, Sees Cash Outflows
Wall Street Journal LN) Wednesday said it swung to a 2010 pretax profit, but it expects substantial cash outflows in 2011 relating to the planned European launch of its flagship asthma treatment Flutiform in the second half of the year. The company also said it expects … |
View full post on asthma – Google News
|
AZ withdraws asthma drug, bad news for SkyePharma
Pharma Times AstraZeneca is to discontinue production of the pressurised metered dose inhaler version of its asthma treatment Pulmicort as a result of manufacturing problems. The Anglo-Swedish drugmaker says the decision has been taken to pull Pulmicort pMDI … Astra pulls asthma product, hitting SkyePharma AstraZeneca ends production of Pulmicort inhaler, hitting shares in partner … |
View full post on asthma – Google News
|
Astra pulls asthma product, hitting SkyePharma
Reuters L) is ending production of the pressurised metered dose inhaler version of its asthma drug Pulmicort, due to technical problems, in a move that will hit its technology partner SkyePharma (SKP.L). SkyePharma developed the formulation for the medicine … |
View full post on asthma – Google News
|
Skyepharma Confirms 2010 Guidance, Sees Fall In 2011 Revenues
Wall Street Journal In August, SkyePharma PLC's partner Abbott Laboratories (ABT) pulled out of development of the asthma treatment due to the lack of progress. |
View full post on asthma – Google News